CN111868086B - 抗lif抗体及其用途 - Google Patents

抗lif抗体及其用途 Download PDF

Info

Publication number
CN111868086B
CN111868086B CN201780086859.0A CN201780086859A CN111868086B CN 111868086 B CN111868086 B CN 111868086B CN 201780086859 A CN201780086859 A CN 201780086859A CN 111868086 B CN111868086 B CN 111868086B
Authority
CN
China
Prior art keywords
amino acid
acid sequence
seq
certain embodiments
lif
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780086859.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN111868086A (zh
Inventor
琼·塞奥尼苏亚雷斯
茱蒂特·艾尼多弗古艾拉
约翰·弗兰松
让-菲利普·朱利安
斯威萨·拉曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institucio Catalana de Recerca i Estudis Avancats ICREA
Fundacio Privada Institut dInvestigacio Oncologica Vall dHebron
MedImmune Ltd
Original Assignee
Institucio Catalana de Recerca i Estudis Avancats ICREA
Fundacio Privada Institut dInvestigacio Oncologica Vall dHebron
Mosaic Biomedicals SL
MedImmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institucio Catalana de Recerca i Estudis Avancats ICREA, Fundacio Privada Institut dInvestigacio Oncologica Vall dHebron, Mosaic Biomedicals SL, MedImmune Ltd filed Critical Institucio Catalana de Recerca i Estudis Avancats ICREA
Priority to CN202410972902.5A priority Critical patent/CN118652335A/zh
Priority claimed from PCT/IB2017/001677 external-priority patent/WO2018115960A1/en
Publication of CN111868086A publication Critical patent/CN111868086A/zh
Application granted granted Critical
Publication of CN111868086B publication Critical patent/CN111868086B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201780086859.0A 2016-12-19 2017-12-18 抗lif抗体及其用途 Active CN111868086B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202410972902.5A CN118652335A (zh) 2016-12-19 2017-12-18 抗lif抗体及其用途

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP16382617.5 2016-12-19
EP16382617 2016-12-19
US201762467017P 2017-03-03 2017-03-03
US62/467,017 2017-03-03
EP17382683 2017-10-13
EP17382683.5 2017-10-13
PCT/IB2017/001677 WO2018115960A1 (en) 2016-12-19 2017-12-18 Antibodies against lif and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202410972902.5A Division CN118652335A (zh) 2016-12-19 2017-12-18 抗lif抗体及其用途

Publications (2)

Publication Number Publication Date
CN111868086A CN111868086A (zh) 2020-10-30
CN111868086B true CN111868086B (zh) 2024-07-16

Family

ID=67138942

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202410972902.5A Pending CN118652335A (zh) 2016-12-19 2017-12-18 抗lif抗体及其用途
CN201780086859.0A Active CN111868086B (zh) 2016-12-19 2017-12-18 抗lif抗体及其用途

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202410972902.5A Pending CN118652335A (zh) 2016-12-19 2017-12-18 抗lif抗体及其用途

Country Status (24)

Country Link
US (2) US11390670B2 (enExample)
EP (2) EP4321219A3 (enExample)
JP (3) JP7100056B2 (enExample)
KR (3) KR102716931B1 (enExample)
CN (2) CN118652335A (enExample)
AU (1) AU2017381585B2 (enExample)
BR (1) BR112019012691A2 (enExample)
CA (1) CA3047528A1 (enExample)
CL (2) CL2019001717A1 (enExample)
DK (1) DK3555132T3 (enExample)
ES (1) ES2971126T3 (enExample)
FI (1) FI3555132T3 (enExample)
HR (1) HRP20240195T8 (enExample)
HU (1) HUE065241T2 (enExample)
IL (2) IL294088B2 (enExample)
LT (1) LT3555132T (enExample)
MX (2) MX2019007376A (enExample)
NZ (1) NZ755004A (enExample)
PL (1) PL3555132T3 (enExample)
RS (1) RS65187B1 (enExample)
SA (1) SA519402119B1 (enExample)
SI (1) SI3555132T1 (enExample)
SM (1) SMT202400065T1 (enExample)
ZA (1) ZA201904533B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS65187B1 (sr) * 2016-12-19 2024-03-29 Medimmune Ltd Antitela na lif i njihove primene
US20210130453A1 (en) * 2018-04-12 2021-05-06 Medimmune Limited Combination of lif inhibitors and pd-1 axis inhibitors for use in treating cancer
EP4069736A1 (en) * 2019-12-04 2022-10-12 MedImmune Limited Antibodies against lif and uses thereof
TWI841810B (zh) 2020-01-24 2024-05-11 日商西斯美股份有限公司 提升抗體對抗原之親和性的方法及其用途
KR20230125037A (ko) 2020-12-31 2023-08-28 노나 바이오사이언시즈 (수조우) 컴퍼니 리미티드 인간 lifr 항원 결합 단백질, 이의 제조 방법, 및 이의응용
EP4337317A1 (en) * 2021-05-14 2024-03-20 Genentech, Inc. Agonists of trem2

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993023556A1 (en) * 1992-05-08 1993-11-25 Genentech, Inc. Antibodies to leukemia inhibitory factor
CN103797031A (zh) * 2010-04-05 2014-05-14 瓦尔德希伯伦肿瘤研究所 识别人类白血病抑制因子(lif)的抗体和抗lif抗体在与有害细胞增殖相关疾病的治疗中的应用

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
WO1993023665A1 (en) 1992-05-15 1993-11-25 Re/Map Incorporated Electromagnetic shielding for a liquid conditioning device
WO1994029351A2 (en) 1993-06-16 1994-12-22 Celltech Limited Antibodies
ES2254564T3 (es) 1995-04-24 2006-06-16 Genentech, Inc. Uso de antagonistas de factor de inhibicion de la leucemia.
KR101077001B1 (ko) 1999-01-15 2011-10-26 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
US6399857B1 (en) * 1999-09-22 2002-06-04 Paradigm Genetics, Inc. Modified nucleotide sequence encoding a LexA DNA binding domain optimized for arabidopsis species
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
EP1497445A2 (en) 2002-04-01 2005-01-19 Human Genome Sciences, Inc. Antibodies that specifically bind to gmad
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP1612558A1 (en) 2004-06-30 2006-01-04 Academisch Ziekenhuis Leiden Method for detecting gluten
AU2006239860B2 (en) 2005-04-25 2012-01-19 Amgen Fremont Inc. Antibodies to myostatin
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
KR20090088871A (ko) 2006-10-04 2009-08-20 더 스크립스 리서치 인스티튜트 인간 메타뉴모바이러스를 중화시키는 인간 항체
CN101440128A (zh) 2007-11-21 2009-05-27 中国人民解放军第二军医大学 人脑胶质瘤中差异表达的蛋白及其用途
CA2742968C (en) * 2008-11-07 2020-06-09 Fabrus Llc Combinatorial antibody libraries and uses thereof
ES2363358B1 (es) 2009-04-03 2012-06-21 FUNDACIÓ INSTITUT DE RECERCA HOSPITAL UNIVERSITARI VALL D'HEBRON (Titular al Agentes terapéuticos para el tratamiento de enfermedades asociadas con una proliferación celular indeseable.
US8221753B2 (en) * 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
JP2013506686A (ja) 2009-09-30 2013-02-28 プレジデント アンド フェロウズ オブ ハーバード カレッジ オートファジー阻害遺伝子産物の変調によりオートファジーを変調する方法
WO2011057144A2 (en) 2009-11-06 2011-05-12 La Jolla Institute For Allergy And Immunology Methods for modulating lif activity, treating immune disorders and diseases, and stimulatings immune responses
CN102167742B (zh) 2010-02-25 2014-05-14 上海百迈博制药有限公司 一种全人源抗her2单克隆抗体、其制备方法及用途
US9790268B2 (en) 2012-09-12 2017-10-17 Genzyme Corporation Fc containing polypeptides with altered glycosylation and reduced effector function
RU2708314C2 (ru) 2013-03-11 2019-12-05 Джензим Корпорейшн Гипергликозилированные связывающие полипептиды
US20140314741A1 (en) 2013-04-18 2014-10-23 Developmen Center For Biotechnology Human Antibody against Interleukin-20 and Treatment for Inflammatory Diseases
EP3037434B1 (en) 2013-08-20 2018-07-18 Japan Science and Technology Agency Human antibody kappa type light chain complex-containing composition and method for producing same
US20150056195A1 (en) 2013-08-23 2015-02-26 Inserm (Institut National De La Sante Et De La Recherche Medicale) Compositions and methods for inihibiting tumorigenicity of senescent cancer cells induced by chemotherapy
WO2015040243A2 (en) 2013-09-23 2015-03-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for targeting tumor microenvironment and for preventing metastasis
US10808026B2 (en) 2013-10-09 2020-10-20 Research Development Foundation Monoclonal Olfml-3 antibodies and uses thereof
TWI486172B (zh) 2013-11-08 2015-06-01 Univ Chang Gung 鼻咽癌治療的醫藥
EP3092253B1 (en) 2014-01-10 2021-03-17 AnaptysBio, Inc. Antibodies directed against interleukin-33 (il-33)
EP3129067B1 (en) 2014-03-19 2023-01-04 Genzyme Corporation Site-specific glycoengineering of targeting moieties
AU2015314980A1 (en) 2014-09-10 2017-03-02 The Regents Of The University Of California Targeting K-Ras-mediated signaling pathways and malignancy by anti-hLIF antibodies
EP3173483A1 (en) * 2015-11-27 2017-05-31 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Agents for the treatment of diseases associated with undesired cell proliferation
US10583191B2 (en) * 2016-12-19 2020-03-10 Mosaic Biomedicals Slu Antibodies against LIF and uses thereof
RS65187B1 (sr) * 2016-12-19 2024-03-29 Medimmune Ltd Antitela na lif i njihove primene
US20210130453A1 (en) * 2018-04-12 2021-05-06 Medimmune Limited Combination of lif inhibitors and pd-1 axis inhibitors for use in treating cancer
WO2019243898A2 (en) * 2018-06-18 2019-12-26 Mosaic Biomedicals Slu Methods for improving response to anti-lif antibody treatment in individuals with cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993023556A1 (en) * 1992-05-08 1993-11-25 Genentech, Inc. Antibodies to leukemia inhibitory factor
CN103797031A (zh) * 2010-04-05 2014-05-14 瓦尔德希伯伦肿瘤研究所 识别人类白血病抑制因子(lif)的抗体和抗lif抗体在与有害细胞增殖相关疾病的治疗中的应用

Also Published As

Publication number Publication date
EP4321219A2 (en) 2024-02-14
DK3555132T3 (da) 2024-02-05
SI3555132T1 (sl) 2024-04-30
US11390670B2 (en) 2022-07-19
CA3047528A1 (en) 2018-06-28
MX2024003178A (es) 2024-03-25
AU2017381585A1 (en) 2019-07-18
KR20230125099A (ko) 2023-08-28
EP3555132B1 (en) 2023-11-15
CN118652335A (zh) 2024-09-17
LT3555132T (lt) 2024-02-26
US20230042095A1 (en) 2023-02-09
PL3555132T3 (pl) 2024-04-22
ZA201904533B (en) 2024-08-28
CN111868086A (zh) 2020-10-30
IL294088B1 (en) 2023-06-01
IL267450B (en) 2022-07-01
MX2019007376A (es) 2020-02-07
KR20240149987A (ko) 2024-10-15
RS65187B1 (sr) 2024-03-29
BR112019012691A2 (pt) 2019-11-19
ES2971126T3 (es) 2024-06-03
HRP20240195T1 (hr) 2024-04-26
NZ755004A (en) 2025-08-29
JP7100056B2 (ja) 2022-07-12
JP2022130632A (ja) 2022-09-06
CL2019001717A1 (es) 2020-02-28
CL2021000950A1 (es) 2021-11-26
FI3555132T3 (fi) 2024-02-08
HUE065241T2 (hu) 2024-05-28
HRP20240195T8 (hr) 2024-05-24
IL267450A (en) 2019-08-29
IL294088A (en) 2022-08-01
EP4321219A3 (en) 2024-05-15
JP2024075682A (ja) 2024-06-04
IL294088B2 (en) 2023-10-01
KR102599557B1 (ko) 2023-11-07
EP3555132A1 (en) 2019-10-23
AU2017381585B2 (en) 2025-02-13
SMT202400065T1 (it) 2024-03-13
SA519402119B1 (ar) 2023-02-19
US20190352389A1 (en) 2019-11-21
KR102784394B1 (ko) 2025-03-19
KR102716931B1 (ko) 2024-10-15
KR20190122652A (ko) 2019-10-30
JP2020512388A (ja) 2020-04-23
JP7459173B2 (ja) 2024-04-01

Similar Documents

Publication Publication Date Title
US10583191B2 (en) Antibodies against LIF and uses thereof
CN111868086B (zh) 抗lif抗体及其用途
JP7603772B2 (ja) 癌の治療に使用するためのｌｉｆ阻害剤と白金系抗悪性腫瘍剤の組み合わせ
HK40107591A (en) Antibodies against lif and uses thereof
HK40040276B (zh) 抗lif抗体及其用途
HK40040276A (en) Antibodies against lif and uses thereof
EA045781B1 (ru) Антитела к lif и их применения
HK40016422A (en) Antibodies against lif and uses thereof
HK40016422B (en) Antibodies against lif and uses thereof
BR122024020696A2 (pt) Anticorpo recombinante que se liga ao fator inibidor de leucemia e composição farmacêutica compreendendo o referido anticorpo

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20201224

Address after: British county

Applicant after: MEDIMMUNE Ltd.

Applicant after: INSTITUCIO CATALANA DE RECERCA I ESTUDIS AVANCATS

Applicant after: FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA VALL D'HEBRON (VHIO)

Address before: Barcelona, Spain

Applicant before: Mosaic biomedical one man LLC

Applicant before: INSTITUCIO CATALANA DE RECERCA I ESTUDIS AVANCATS

Applicant before: FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA VALL D'HEBRON (VHIO)

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40040276

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant